Pacira BioSciences Reports First Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pacira Pharma (PCRX) Tops Q1 EPS by 22c, Revenues Beat
May 7, 2020 8:09 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.53, $0.22 better than the analyst estimate of $0.31. Revenue for the quarter came in at $105.7 million versus the consensus estimate of $102.82 million.
First Quarter 2020 Financial Results
Total revenues were $105.7 million in the first quarter of 2020, a 16% increase over the $91.3 million reported for the first quarter of 2019.EXPAREL net product sales were $101.3 million in the first quarter of 2020, a 12% increase over the $90.6 million reported for the first quarter of 2019.First quarter iovera° net product sales were $2.3 million. Pacira began recognizing sales of iovera° in April 2019... More